Gilead Sciences (GILD -2.70%) has had a banner year.
Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations.
Celgene (CELG) has had a more mixed experience this year, with concerns about the Revlimid patent and even some less-than-stellar trial data for its up-and-coming drug Otezla.
But Gilead's opportunity is more than just Sovaldi, and Celgene's is more than just Revlimid (and even more than just Revlimid and Otezla).
Are they the best big biotechs?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.
